ASIC fibroblast growth factor (bFGF) is a pleiotropic cytokine that plays an important role in angiogenesis and mesodermal development.' Recently, it has been shown that bFGF can also act as a hematopoietic cytokine. It is produced by' and is a potent mitogen for human stromal cells.3 It is found in megakaryocytes and cells of the granulocyte lineage in vivo,' and it enhances megakaryop~iesis~" and myelopoiesis in human long-term bone marrow cultures.' Basic FGF also augments the proliferation of progenitor cells when added in conjunction with other growth facand it counteracts the suppressive effects of transforming growth factor-/? I on human myeloid progenitor cells." In addition, receptors for FGF have been found to be expressed on normal human megakaryocytes and some myeloid leukemic
Recently, increased levels of bFGF have been detected in urine from patients with a broad variety of neoplastic diseases, including various leukemia^.'^,'^ Chronic lymphocytic leukemia (CLL), a disease characterized by delayed senescence and the slow accumulation of monoclonal (CDS-positive, CD 19-positive), mature, small lymphocytes, the major- ity of which are nondividing. It has been suggested that a prolonged life span is a major factor in the accumulation of these leukemic cells." In this regard, it is of interest that bFGF has recently been shown to delay apoptosis in endothelial cells."
These observations prompted us to explore whether intracellular levels of bFGF were elevated in CLL cells and whether, in turn, these elevated levels contributed to the enhanced survival of CLL lymphocytes.
MATERIALS AND METHODS

Reagents. Fludarabine
(9-P-D-arabinosyl-2-fluoroadeninemonophosphate) was obtained from Berlex (Richmond, CA). It was freshly resuspended according to the manufacturer's guidelines and added to tissue culture media. Fludarabine des-phosphate (F-Ara-A; 9-P-D-arabinosyl-2-fluoroadenine) was obtained from Sigma Chemicals (St Louis, MO). Recombinant human basic fibroblast growth factor (rhbFGF) was a gift from Synergen Inc (Boulder, CO). Stock vials were stored at -20°C. For each experiment, all reagents were diluted in serum-containing medium on the day of use.
Patients/staging. Samples were obtained from 36 patients with documented B-CLL after informed consent. Samples of 15 normal individuals were also collected. Of the 36 patients, 22 presented for evaluation and potential enrollment in an ongoing clinical trial at Memorial Sloan-Kettering Cancer Center (New York, NY) designed for CLL patients with intermediate-and high-risk disease; the other 14 patients were seen as part of their initial visit or routine follow up. Patient selection was based on the diagnosis of B-CLL. The selection of patient samples for in vitro evaluation was based on the volume of blood received in the laboratory on a given patient and, thereby, the number of cells from the sample received. The comparison in each risk group for age, white blood cell (WBC) counts, or intracellular bFGF content between the samples evaluated in vitro and the samples only examined for intracellular content did not reveal any significant difference. Furthermore, no bias for age or WBC count between the three risk groups was detected. None of the patients bad received chemotherapy for at least 3 months before obtaining the samples. Clinical staging was performed according to the modified Rai staging system.'' Cells. Peripheral blood was drawn into EDTA-containing tubes (Becton Dickinson, Rutherford, NJ). The serum was removed after a brief centrifugation and stored at -20°C and the cell pellet was resuspended in an equal amount of phosphate-buffered saline (PBS). The mononuclear cells were isolated by centrifugation on FicollHypaque gradients (1.077 g/mL; Pharmacia Fine Chemicals, Piscataway, NJ), washed three times in PBS, and suspended in standard media (RPM11640 media) containing 10% heat-inactivated fetal calf serum (FCS; GIBCO, Grand Island, NY) supplemented with penicillin (100 U/mL; GIBCO), streptomycin (100 pg/mL; GIBCO), and 3 mg/mL of glutamine (GIBCO). The cell count was determined microscopically using a hemocytometer. The cells were resuspended in either 90% FCS (GIBCO)/lO% dimethyl sulfoxide (DMSO; Sigma) and stored under liquid nitrogen until further use or cultured in standard media. An aliquot of lo6 cells was pelleted in siliconized Eppendorf tubes, supernatant was removed, and cells were stored at -80°C. Cell lysates were prepared by resuspending the cells with 1 .O mL of RPM11640 containing 0.1% bovine serum albumin (BSA), shockfreezing in liquid nitrogen, and thawing at 37"C, followed by vigorously vortexing the suspension. This procedure was repeated three times. Subsequently, the suspension was centrifuged at 3,000 rpm, and the supematant was removed and stored at -80°C.
Cell culture. Cells were suspended in standard media. Fludarabine was added on day 1 at a final concentration of 0.3, 3, or 30 pmol/L, respectively, to the specified culture. Basic FGF diluted in standard media was added daily to each condition at a final concentration of IO or 100 ng/mL. The same amount of standard media alone was added to all other conditions. The incubation was performed for 7 days at 37°C in 5% CO,. Cell viability was assessed by trypan blue (GIBCO) exclusion using a hemocytometer. Each sample was evaluated in duplicate. The percentage of viable cells in treated samples (treated with fludarabine with or without bFGF) was divided by the average viability of the untreated (standard media alone) samples (controls) at the same time.
Measurement of bFGF levels. Cell lysates and EDTA plasma samples (200 pL per well) were tested for the presence of bFGF by a sandwich enzyme-linked immunosorbent assay (ELISA; R&D Systems, Minneapolis, MN) that has a detection limit of 1 pg/mL. Briefly, 200 pL of cell lysate or standard rhbFGF (5 pg/mL to 640 pg/mL) was pipetted into wells precoated with a monoclonal antibFGF antibody. After a 2-hour incubation period at room temperature (RT), the wells were washed three times, and a secondary enzyme-bound polyclonal anti-bFGF antibody was added to the wells. After another 2-hour incubation at RT, wells were washed again, and substrate solution was added. The color reaction was stopped after 20 minutes. Absorption at 450 nm was measured immediately in an automated ELISA reader (Emax-Reader; Molecular Devices, Menlo Park, CA). Basic FGF content was calculated using an analytical program (Softmax; Molecular Devices, Sunnyvale, CA).
Morphologic detection of apoprosis. Cells (5 X IO') were cytocentrifuged at 500 rpm for 7 minutes using a cytocentrifuge (Cytospin 2; Shandon Inc, Pittsburgh, PA). The cells were fixed and stained using the Diff-Quick-Kit (Baxter Healthcare Corp, Miami, FL) and examined for morphologic changes consistent with apoptosis, such as nuclear compaction and fragmentation, cytoplasmatic condensation, and the formation of apoptotic bodies and surface protuberances on cellular membranes.
In situ terminal deoxynucleotidyl transferase (TdT) assay. The in situ TdT assay was performed as previously described." Briefly, aliquots of cells were collected from liquid culture, centrifuged, and fixed in 0.3% buffered formaldehyde (pH 7.5). After washing with PBS, cells were resuspended in 70% ethanol (-20°C) and stored at -20°C. After rehydration with PBS, the cells were resuspended in 50 pL cacodylate buffer containing 0.2 m o m potassium cacodylate, 2.5 mrnol/L Tris-HCI (pH 6.6), 2.5 mmoVL cobalt chloride (CoCI,), 0.25 mg/mL BSA, 7.5 U of TdT, and 0.5 nmol biotinylated deoxyuracil-triphosphate (b-dUTP; all reagents from Boehringer M mheim). After incubating the cells in this solution for 30 minutes at 37"C, the cells were washed with PBS; resuspended in 100 pL of a solution containing 4X SSC (saline-sodium citrate buffer), 25 pg/ mL avidin-fluorescein isothiocyanate (avidin-FITC; Boehringer Mannheim), 0.1% Triton X-100, and 5% wtlvol non-fat dry milk;
and incubated for 30 minutes in the dark at RT. Cells were washed with PBS containing 0.1% Triton X-l00 and resuspended in 0.5 mL PBS containing 5 pg/mL propidium iodine (Sigma) and 0.1 % RNAse A (Sigma). Green fluorescence detecting FITC levels and red fluorescence measuring propidium iodine content of individual cells were quantified on a FACStar (Becton and Dickinson): data from 2 X lo4 cells were collected and used for analysis.
Analysis of cell surface markers. Analysis of cell surface markers was performed on a Coulter Epic Profile I (Hialeah, FL). Flow cytometric analysis and monoclonal antibodies used have been described in detail elsewhere.''
Immunojuorescence. Immunofluorescence was performed as described by Brunner et al.' Briefly, mononuclear cells were isolated by centrifugation on Ficoll-Hypaque gradients. Then, 5 X los cells were cytocentrifuged at 500 rpm for 7 minutes using a cytocentrifuge (Cytospin 2; Shandon Inc) and fixed at -20°C with methanol (5 minutes) followed by fixation with acetone for 2 minutes. Fixed slides were washed with PBS and stored at 4°C. Before immunofluorescence staining, nonspecific protein binding sites were blocked by incubation with 5% (wt/vol) dry milk in PBS for 2 hours at 37°C followed by a l-hour incubation with 20% (vol/vol) goat serum (Sigma) in PBS containing 1.5 mg/mL human IgG (Sigma) to saturate Fc receptor sites. Cells were then incubated with polyclonal rabbit anti-bFGF antiserum (Sigma: diluted 1:5 with PBS containing 5% dry milk) or irrelevant rabbit antiserum (negative control) for 1 hour at 37"C, followed by incubation with goat anti-rabbit IgG conjugated to FITC (Sigma; 1 2 0 in PBS containing 5% dry milk). After washing and air-drying, cells were embedded in polyvinyl alcohol (Airvol; Air Products and Chemicals, Allentown, PA) and examined using a fluorescence microscope. Photographs were taken on Kodak Ektachrome 400 ASA (Eastman Kodak CO, Rochester, NY) at 100 X magnification with oil using a Zeiss photomicroscope (Filter: Hoechst 11) with automatic time exposure.
Statistical analysis. Student's unpaired t test or Mann-Whitney rank sum test was used to estimate statistical significance between the different groups whenever applicable. The paired t test or Wilcoxon's signed rank test were used to estimate statistical significance between cells treated with fludarabine alone and those treated with fludarabine plus bFGF.
RESULTS
A total of 36 patients with documented B-CLL and 15 healthy volunteers were included in the study. Of the 36 patients (female, n = 13; male, n = 23), 8 presented with low-risk, 14 with intermediate-risk, and 14 with high-risk disease." The median age was 65.5 years (range, 38 to 85 years); median WBC count at presentation was 55.2 X lo3/ pL, with a range of 2.5 X lO"/pL to 217 X 103/pL ( Table  1) . Flow cytometry analysis indicated that B-CLL cells coexpressed CD5, CD19, and CD20.
In cells derived from patients with high-risk disease, the median level of intracellular bFGF (per 2 X lo5 cells) was 381.5 pg (range, 134.1 to 732.2 pg). Levels were found to be lower in patients with intermediate-risk disease, with a median of 90.51 pg (range, 3.3 to 373.4 pg). In patients with low-risk disease (Rai, low risk) the median bFGF level (per 2 X lo5 cells) was 4.9 pg (range, 1.5 to 22.6 pg). Lymphocytes from healthy volunteers exhibit a comparable median intracellular bFGF level of 6.0 pg (range, 0.8 to 17 pg) to All patients (n = 36) that found in CLL cells derived from patients with low-risk disease (Fig 1) .
Intracellular bFGF levels in lymphocytes from CLL patients with advanced-stage disease (modified Rai classification, high risk) were significantly higher than bFGF levels detected in cell lysates from normal controls (P < Immunofluorescence staining was performed to confirm that CLL lymphocytes were the actual cellular source of bFGF. Immunofluorescence stains of cells derived from patients with low-, intermediate-, and high-risk disease are shown in Fig 2. The morphology of the fluorescent cells is consistent with CLL lymphocytes. Strong cytoplasmatic staining can be seen in the CLL cells derived from a patient with high-risk disease ( Fig 2D) ; lesser staining occurs in the cytoplasm of cells obtained from a patient with intermediaterisk disease (Fig 2C) . The cytoplasm of cells from a patient with low-risk disease is only faintly stained (Fig 2B) . This cytoplasmic fluorescence observed in these patients' cells was consistent with the results obtained with the ELISA (Fig  1) . Peripheral blood lymphocytes from a healthy donor are shown in Fig 2A. Only very weak cytoplasmic staining is seen in these cells, demonstrating that the bFGF content of normal lymphocytes is equivalent to that found in low-risk CLL cells. In addition, it does not differ from rabbit IgG controls (data not shown), suggesting that these cells do not contain a significant amount of bFGF.
We next evaluated the effects of intracellular bFGF on the life span of CLL cells. No correlation between the intra- We then examined whether the viability of CLL cells exposed to an apoptotic stimulus could be related to the intracellular bFGF content. For these experiments, B-CLL lymphocytes were cultured in vitro for 7 days in the presence or absence of fludarabine, a chemotherapeutic drug inducing apoptosis in CLL cells?' When CLL lymphocytes were exposed to three different concentrations (0.3, 3.0, and 30 pmol/L), cell viability decreased abruptly at 30 pmol/L. At a concentration of 3 pmol/L, fludarabine-induced cell death was as effective, but the decrease in viability was slower. Fludarabine at 0.3 pmoVL did not yield to any significant decrease in cell viability (data not shown). We, therefore, chose a fludarabine concentration of 3 pmol/L for subsequent experiments.
B-CLL cells from 19 patients were exposed to fludarabine alone and evaluated for viability. Trypan blue exclusion analysis revealed a significant difference in the survival of B-CLL cells when the results were compiled according to the intracellular bFGF content (Table 2) Table 2 ). On day 7 of culture in the presence of fludarabine (3 pmoVL), the percentages of viable cells were 16%, 24%. and 46% for cells containing low, intermediate, or high intracellular bFGF, respectively. These differences were significant ( P = .0063) between cells containing high and low levels of bFGF, and between cells containing intermediate and high levels of bFGF ( P = .0114; Table 2 ). Further statistical evaluation of the association between intracellular bFGF content and resistance to fludarabine suggested arranging the samples into two groups containing either less than 134 pg/2 X l@ cells or more than 234 pg/2 X lo5 cells, respectively (Table 3 ; in the patients' B-CLL cells evaluated in vitro, no values between 134 pp/ 2 X lo5 cells and 234 pg/2 X lo5 cells were measured). On day 4, 47% of the cells in the group with an intracellular bFGF content between 1.5 and 134 pg/2 X lo5 cells were viable, compared with 64% of the cells with an intracellular bFGF content between 234 and 732 pg12 X 10' cells. On day 7, only 19% of B-CLL cells with the lower intracellular bFGF content were still viable, as compared with 46% of the cells with higher intracellular bFGF content. The calculated P values for the differences in survival on day 4 and day 7 were significant ( P = .0282 and .0041, respectively).
We next tested whether the addition of exogenous bFGF at different concentrations (1, 10, 100 ng/mL) to B-CLL cells could increase their resistance to fludarabine. Adding bFGF to the fludarabine-treated CLL cells resulted in an increased survival that was most distinct at a bFGF concentration of 100 ng/mL. As shown in Table 4 , the survival of fludarabine-treated CLL cells containing low intracellular bFGF (1.5 to 6 pg/2 X lo5 cells) was significantly increased by the addition of exogenous bFGF. The addition of exogenous bFGF resulted in a 10% increase in viable cells on day 1. On day 2, 68% of the cells treated with fludarabine alone were viable, whereas cells treated with fludarabine plus bFGF displayed 81% viability (Table 4 ). After 7 days of culture in the presence of fludarabine, 16% of the cells were * Student's t-test was used to determine the P values. Viability of B-CLL cells in standard medium treated with fludarabine (3 wmol/L) alone or plus bFGF (100 ng/mL). Each patient sample was evaluated in duplicate. Numbers represent the mean and standard deviation of the group of patients for each respective bFGF content.
See notes to Table 2 for definitions of intracellular bFGF content.
* The paired t-test was used to determine the P values.
viable, compared with 47% of the cells treated with fludarabine plus bFGF. These differences in survival were significant. Furthermore, the addition of exogenous bFGF to B-CLL cells containing low intracellular bFGF rendered them as resistant to fludarabine as cells with high intracellular content. B-CLL cells with intermediate bFGF content (45 to 134 pg/2 X 10' cells) treated with fludarabine alone yielded a 50% decrease in viability observed on day 4. When exogenous bFGF was added, this 50% decrease in survival was delayed and was observed, instead, on day 7. This difference in survival of these B-CLL cells was also significant (Table  4) . Interestingly, the addition of 100 ng/mL of exogenous bFGF to B-CLL cells with high intracellular bFGF content (234 to 732 pg/2 X 10' cells) also resulted in a significant increase in cell survival after fludarabine treatment (Table   4) .
No effect on survival was observed in either instance when bFGF was added to CLL cells under standard serum conditions (data not shown).
Since the assessment of viability by trypan blue exclusion does not provide a direct correlation with apoptosis, the morphology of cells treated with fludarabine alone or fludarabine plus bFGF was examined microscopically. Treatment with fludarabine alone for 24 hours resulted in changes consistent with apoptosis, such as nuclear condensation, micronuclei formation, and the appearance of apoptotic bodies (data not shown). These changes were more prominent after 48 hours of exposure, confirming the apoptotic effects of fludarabine that have been previously described.'l In cells treated with fludarabine plus bFGF, morphologic changes consistent with apoptosis were observed only in a small fraction of the CLL lymphocytes (data not shown). To quantify the changes observed, we examined cells treated with or without bFGF for changes in response to an apoptotic stimulus with a recently developed flow cytometric method.19 Apoptosis-associated DNA strand breaks are detected using an in situ TdT assay. The intensity of labeling of apoptotic cells with biotinylated dUTP correlates with the number of DNA strand breaks per cell. Treatment of B-CLL cells from patients with low-risk disease (n = 2) and intermediate-risk disease (n = 2) with F-Ara-A at 3 pmol/L resulted in a significant increase in the percentage of apoptotic cells after 12 and 36 hours (Fig 3) . This increase could be effectively reduced by adding bFGF to the culture. In a representative experiment using CLL cells with low intracellular bFGF, 12 hours of incubation with fludarabine resulted in an increase of the apoptotic cell fraction to 27%. When the cells were treated for 12 hours with fludarabine plus 100 ng/mL of bFGF, the fraction of apoptotic cells was reduced to 18.7%. After 36 hours of incubation with fludarabine, 70% of cells were apoptotic; treatment with fludarabine plus bFGF for 36 hours resulted in only 22.5% apoptotic cells (Fig 3) .
DISCUSSION
This is the first study to (1) demonstrate elevated intracellular bFGF levels in lymphocytes of patients with intermediate-or high-risk CLL, (2) reveal a correlation between the clinical stage of CLL and the level of intracellular expression of bFGF, and (3) show that bFGF may be a contributing factor to the resistance of B-CLL cells to an apoptotic stimulus.
Basic FGF has been postulated to play a role in malignancy." Elevated levels of bFGF have been previously reported in cells derived from renal cell carcinomaz3 and malignant melanoma,z4 and a correlation between increased levels and impaired prognosis25 has been established. Other investigators have shown increased urinary excretion of bFGF in a variety of neoplastic diseases, including leukemias14; however, the source of the bFGF was not established. In this study, lymphocytes from patients with CLL were identified as a source of bFGF. In addition, the intracellular bFGF level correlated with the stage of the disease, suggesting that in the course of the disease, the accumulation of intracellular bFGF provides an advantage for malignant cells. As the size of a leukemic cell population is regulated not only by proliferation but also by the rate of cell death, a delay in apoptosis caused by elevated bFGF levels may create a survival advantage.
Recently, evidence has emerged that bFGF may be able to interfere with apoptosis. Apoptosis is a selective process of physiologic cell depletion. It is characterized by intranucleosomal DNA cleavage, chromatin condensation, and a reduction in cell size.26 Cell lines that are consistently overexpressing bFGF after stable transfection with the gene for bFGF show a marked delay in apoptosis after serum starvation.268 Adding bFGF to the culture media immediately after inducing apoptosis by radiation in bovine endothelial cells resulted in a significant increase in survival at different
For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From levels of radiati~n.'~ In addition, Fuks et all7 demonstrated a protective effect of bFGF in mice receiving total lung radiation. When bFGF was given intravenously before and shortly after radiation, development of radiation-induced pneumonitis was impaired, and samples of irradiated tissue exhibited a lower content of apoptotic cells.
In this study, we were able to demonstrate that higher intracellular bFGF content was associated with an increased resistance to fludarabine-induced apoptosis in vitro. Furthermore, the addition of exogenous bFGF to fludarabine-treated B-CLL cells with lower intracellular bFGF levels yielded delayed apoptosis and increased cell viability similar to that observed for CLL cells with higher intracellular bFGF content. CLL cells with a lower intracellular bFGF content treated with exogenous bFGF cells mimic the phenotype observed in cells containing higher intracellular bFGF content. Moreover, the addition of exogenous bFGF to fludarabine-treated cells with high intracellular bFGF content further increased the survival of these cells, suggesting that the mechanism by which bFGF exerts its effect may be mediated at least in part from the extracellular compartment. These initial observations are promising and will require a larger clinical study to further validate their importance.
Inhibition of apoptosis appears to play an important role in the clonal expansion, tumor progression, and resistance to cytotoxic therapy in CLL. Alterations in specific gene products involved in the regulation of apoptosis have previously been reported in CLL, including deletions of the retinoblastoma gene (Rb)." increased expression of bcl-2, most often in the absence of a specific translocation,28 and mutations in p53.29,"' Several cytokines have also been shown individually to protect B-CLL cells from undergoing programmed cell death. Interferon-a has been shown to increase bcl-2 expression in B-CLL cells, resulting in a delay of apoptosis in vivo and in vitro." In addition, interferony'2 and interleukin-43' have been shown to inhibit apoptosis of CLL cells and promote survival of cells in vitro. More recently, increased expression of cyclin D2 has been found in CLL, suggesting that this may contribute to the delayed senescence characteristic of this disease. These reports suggest that the potential effects of bFGF on delaying apoptosis and prolonging the survival of B-CLL cells may be indirect, via the induction of one or more of these cytokines or inhibition of specific genes that promote apoptosis. This remains to be determined.
Basic FGF may function as an independent factor or work in concert with one or more of the cytokines or genetic alterations reported to be operative in CLL.3" Therefore, the expression and biologic activity of bFGF needs to be studied in the context of the expression of other cytokines and gene products involved in the regulation and pathogenesis of this disease. This is presently an area of active investigation in our laboratory.
